|
Patent landscape, scope, and claims: |
US Patent 8,648,037 (Drug) | Scope, Claim Set, and US Patent Landscape for a Formula I-to-XH HCV NS3 Protease Inhibitor
What is the claimed invention in US 8,648,037?
US Patent 8,648,037 claims a family of small-molecule compounds defined by broad Formula I (and multiple dependent sub-formulas), including pharmaceutically acceptable salts. The claimed structures are framed as HCV NS3 protease inhibitors, with downstream claims covering pharmaceutical compositions and methods of treating hepatitis C and inhibiting replication of hepatitis C virus.
The independent claim is Claim 1, which is a generic chemical Markush-style definition using variables (A, B, M1, M2, R1, L1, L2, W, X/Y/X’, R3, R4/R5, R/R’, G, R’’) over wide structural classes. Claims 2 to 6 further narrow or specify sub-variants (Formula II, III/IV, VI, VII) by adding constraints on substituents (notably X1-X4, Yi/Y2, Yi/Y3, and ring-closure rules).
Independent/duplicated late claims then recite additional formula variants (Claims 17 and 20) and compound subsets (Claim 23 references Formula VIII + salts, tied to a Table 1 listing compounds).
How broad is Claim 1, in claim-language terms?
Claim 1 defines a compound “of Formula I: or a pharmaceutically acceptable salt thereof,” where major structural degrees of freedom are open:
Key variable gates in Claim 1
- Core substitution at A: A is absent or one of:
- —(C═O)—
- —S(O)2—
- —C(═N—OR1)—
- —C(═N—CN)—
- B ring class (marked “{circle around (B)}”):
- —C3-C12 cycloalkyl (substituted allowed)
- —C3-C12 cycloalkenyl (substituted allowed)
- —C3-C12 heterocycloalkyl (substituted allowed)
- —C3-C12 heterocycloalkyl (substituted allowed)
- M1 and M2:
- each is independently O or NR1
- R1: at each occurrence from a broad heteroatom-containing organic set:
- H; aryl/substituted aryl; heteroaryl/substituted heteroaryl
- heterocycloalkyl/substituted heterocycloalkyl
- or C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, each with 0-3 heteroatoms chosen from O/S/N (and corresponding substituted variants)
- plus cycloalkyl/cycloalkenyl classes and substituted analogs
- L1 and L2 linkers:
- —C1-C8 alkylene / —C2-C8 alkenylene / —C2-C8 alkynylene with 0-3 heteroatoms (O/S/N)
- or cycloalkylene/cycloalkenylene analogs with the same heteroatom allowance
- W:
- absent or —O—, —S—, NH—, —N(Me)—, —C(O)NH—, or —C(O)N(Me)—
- X and Y:
- taken together with the carbon atoms they attach to form a cyclic moiety selected from:
- aryl, substituted aryl, heteroaryl, substituted heteroaryl,
- heterocyclic, substituted heterocyclic
- X’:
- R3:
- C1-C8 alkyl or C2-C8 alkenyl or C2-C8 alkynyl with 0-3 O/S/N heteroatoms, plus substituted versions
- or cycloalkyl/cycloalkenyl and substituted analogs
- also heteroaromatic sets (heterocyclic/aryl/heteroaryl terms included)
- R4 and R5:
- H and/or R3 (each independently)
- R and R′:
- broad, including saturated/unsaturated C-chain groups with up to 3 heteroatoms,
- cycloalkyl/cycloalkenyl/alkylcycloalkyl/alkylcycloalkenyl,
- aryl/substituted aryl,
- heteroaryl/substituted heteroaryl,
- heterocycloalkyl/substituted heterocycloalkyl,
- and hydrogen/deuterium allowed in one branch
- G (terminal functional):
- —OH
- —NHS(O)2—R3
- —NH(SO2)NR4R5
- NR4R5
- R’’:
- hydrogen, methyl, ethyl, allyl
Practical effect
Claim 1 is a very large chemical space definition. The combination of:
- multiple permissive substitution positions (R1 at multiple occurrences, R3 at multiple occurrences),
- flexible ring/linker classes,
- and broad terminal functional sets (G)
means hundreds to thousands of distinct structures could sit within the literal scope, depending on the exact geometry of Formula I’s drawn scaffold.
What does Claim 2 add (Formula II specification)?
Claim 2 depends from Claim 1, stating the compound is of Formula II and introduces X1-X4:
- X1-X4 are independently —CR6 or N
- R6 is independently from:
- H; halogen; —NO2; —CN; N3
- or —M-R3 where M is O, S, or NH
- or NR4R5
- or C1-C8 alkyl / C2-C8 alkenyl / C2-C8 alkynyl with 0-3 O/S/N heteroatoms (and substituted variants)
- or cycloalkyl/cycloalkenyl and substituted analogs
- or aryl/substituted aryl; heteroaryl/substituted heteroaryl
- or heterocycloalkyl/substituted heterocycloalkyl
Claim 2 then reiterates the same big Claim 1-style variable sets for A, B, M1/M2, R1, L1/L2, W, X’, R3, R4/R5, R/R’, G, R’’ with only the added constraint: X1-X4 and R6 set.
What does Claim 3/4 add (Formula III/IV, VI)?
- Claim 3: compound is Formula III or IV
- each Y1 and Y2 selected from —CR6 or N
- Y3 selected from NR6, S, O
- each R6 set matches Claim 2’s R6 menu
- plus the same Claim 1 architecture (A/B/M1/M2/R1/L1/L2/W/X’/R3/R4/R5/R/R’/G/R’’)
- Claim 4: compound is Formula VI with the same X1-X4 and R6 framework as Claim 2.
What does Claim 5 add (Formula VII)?
- Claim 5: compound is Formula VII
- introduces ring-combination rules: “R1, R2, R3, and R4’ are each independently R6, or R1’ and R2’, R2’ and R3’, or R3’ and R4’ combined together with the carbons they are attached to form aromatic or heteroaromatic or cyclic or heterocyclic ring”
- uses R6 again as the main substituent menu (halogens, nitro, cyano, azide, —M-R3, NR4R5, alkyl/alkenyl/alkynyl chains with O/S/N heteroatoms, cycloalkyl/cycloalkenyl, aryl/heteroaryl, heterocycloalkyl)
- includes a special rule for R4 and R5:
- independently selected from H and R3, or
- R4 and R5 taken together with the nitrogen atom form a heterocyclic ring
- maintains the rest of the Claim 1 variable system plus R’’ options.
What does Claim 7 do (pharma composition)?
- Claim 7: A pharmaceutical composition comprising:
- a compound according to Claim 1 or a pharmaceutically acceptable salt thereof
-
- a pharmaceutically acceptable carrier/excipient.
What does Claims 8-16 do (HCV treatment/replication inhibition and add-on regimens)?
- Claim 8: method of treating HCV infection in a subject needing treatment, by administering a therapeutically effective amount of a Claim 1 compound.
- Claim 9: method of inhibiting replication of HCV by contacting virus with an HCV virally effective NS3 protease inhibitory amount of the composition (composition mentions Claim 1 compound).
- Claim 10: Claim 8 plus concurrent administration of an additional anti-HCV agent.
- Claim 11: additional agent selected from:
- α-interferon, β-interferon, ribavarin, adamantine.
- Claim 12: additional agent is inhibitor of:
- hepatitis C virus helicase, polymerase, metalloprotease, or IRES.
- Claim 13: pharmaceutical composition of Claim 7 plus another anti-HCV agent.
- Claim 14: pharmaceutical composition of Claim 7 plus an agent selected from:
- interferon, ribavirin, amantadine,
- another HCV protease inhibitor,
- an HCV polymerase inhibitor,
- an HCV helicase inhibitor,
- an IRES inhibitor.
- Claim 15: pharmaceutical composition includes pegylated interferon.
- Claim 16: pharmaceutical composition includes another antiviral/anti-bacterial/anti-fungal/anti-cancer agent or an immune modulator.
This claim block positions the patent not only as a “compound claim” but also as a regimen claim framework. From an enforcement standpoint, the broad Markush definition may be less decisive than the “method + co-admin agent classes” language, which can capture combination therapies.
What are Claims 17-22 (additional formula claims and mirrored methods/compositions)?
The later claims repeat the pattern:
- Claim 17: “A compound of the formula or a pharmaceutically acceptable salt thereof” (not fully readable in the user-provided text, but it clearly introduces another formula variant).
- Claim 18: pharmaceutical composition containing the Claim 17 compound.
- Claim 19: treating HCV using the Claim 17 compound.
- Claim 20: another compound of the formula or salt thereof (Formula variant again).
- Claim 21: pharmaceutical composition with Claim 20 compound.
- Claim 22: method of treating HCV with Claim 20 compound.
What does Claim 23 do (explicit compound list via Formula VIII and Table 1)?
- Claim 23: “The compound of claim 1, selected from compounds of Formula VIII… wherein R, -L2-W-L1-, R′ and G for each compound are delineated in Table 1.”
- Table 1 is present but only partially captured in the excerpt; it lists compound numbers 1 through 254 (at least) in the visible portion.
From a landscape perspective, the Table-backed claim matters because it:
- turns a broad Markush concept into a specific captured species set,
- creates a cleaner infringement target for specific candidate molecules that match a listed R/L2/W/L1/R’/G pattern.
Even without the full Table text in your prompt, the presence of a structured Table indicates the patentee likely enumerated a significant subset of exemplified structures.
Where does this patent sit in the US HCV NS3 protease inhibitor landscape?
What therapeutic target is claimed?
The record in your claim text explicitly states:
- NS3 protease inhibitory amounts are used to inhibit replication (Claim 9).
- Methods treat HCV infection (Claims 8, 10, 19, 22).
What does that imply about prior art and typical competitive families?
US HCV NS3 protease inhibitors historically include several structural families. A typical landscape view for US infringement/validity work usually checks:
- earlier patents on NS3 protease inhibitors with similar warheads and cyclic P1/P2 motifs,
- subsequent improvement patents that expand substituent variety and combination regimens.
However, because your prompt includes only the claim text (not the patent title, assignee, filing dates, or the number of independent claims beyond those visible), a rigorous US landscape map with named competitor patents cannot be produced from your input alone.
Per your constraints, the analysis below therefore sticks to what the claim text itself establishes and the enforcement-relevant claim boundaries it creates.
Scope assessment: what competitor molecules are most at risk?
Most at-risk space inside Claim 1
A competitor falls into higher risk if it matches all of the following claim-identity anchors:
- The same scaffold skeleton defined by Formula I geometry, with A selected from the specified carbonyl/sulfonamide/imine-nitrile options.
- B and the cycloalkyl/heterocycloalkyl ring class in the specified C3-C12 ranges and substitution allowances.
- X’ = N and the X/Y ring-closure: X and Y together form an aryl/heteroaryl/cyclic moiety.
- W belongs to the specified set (absent, O/S linkers, amine variants, and amide-like groups).
- G is one of the specified hydroxyl/amidosulfonamide/amine or ammonium-like functionalities.
- R’’ matches H, methyl, ethyl, or allyl.
Where co-administration claims expand practical reach
Even if a competitor’s exact compound skirts literal scope, the method/composition claims still attempt to capture:
- any formulation that uses “a compound according to claim 1” and
- adds broadly defined agents (interferons, ribavarin, adamantine, helicase/polymerase/metalloprotease/IRES inhibitors, other protease inhibitors).
This means business risk also includes combination-product development where the co-agent choice is effectively predetermined by existing standard-of-care classes.
Claim strategy and likely enforceability pressure points
Large Markush breadth increases the “coverage” probability, but creates construction issues
Claim 1’s breadth is high. The most likely enforcement friction usually comes from:
- whether a competitor’s structure fits the exact Markush boundaries (especially A, W, and G),
- whether ring-closure interpretations (X/Y cyclic moiety) match claim construction.
Table 1 species convert ambiguity into concrete infringement targets
Claim 23, tied to Table 1, typically:
- strengthens infringement by letting the patentee point to listed species rather than relying on full Markush parsing,
- improves settlement posture around “known matching candidates.”
Key Takeaways
- US 8,648,037 is a broad HCV NS3 protease inhibitor chemical-entity patent with extensive Markush-style coverage in Claim 1 and formula-specific dependent claims (Claims 2-6).
- The patent’s practical enforcement perimeter extends beyond compound sales through method claims for treating HCV and replication inhibition (Claims 8-9) and through combination regimens with major HCV classes (Claims 10-16).
- Claim 23 plus Table 1 turns part of the broad Markush space into named species coverage by enumerating compound selections via Formula VIII parameterization.
- For competitive targeting, the highest infringement risk concentrates on entities that match the required claim anchors: A, W, G, X’ = N, and the X/Y ring-closure plus the Formula I scaffold geometry.
FAQs
-
Does US 8,648,037 claim only compounds or also uses and combinations?
It claims compounds (Claims 1-6, 17, 20, 23), pharmaceutical compositions (Claim 7, 18, 21), and methods for treating HCV and inhibiting replication, including combination regimens (Claims 8-16).
-
What therapeutic mechanism is explicitly claimed?
It claims “NS3 protease inhibitory amount” for inhibiting HCV replication (Claim 9).
-
Is Claim 1 limited to a narrow set of substituents?
No. Claim 1 is a very broad Markush-style definition with wide ranges for R1, R3, R/R’, linkers L1/L2, and ring classes (B and cyclic moiety from X/Y).
-
Which claim most strengthens infringement on specific structures?
Claim 23, because it selects compounds of Formula VIII with parameters delineated in Table 1.
-
How do the combination therapy claims operate?
Claims 10-16 allow co-administration or composition inclusion with specified classes of anti-HCV agents, including interferons, ribavirin, adamantine, and inhibitors of helicase/polymerase/metalloprotease/IRES, plus other HCV protease inhibitors.
References
[1] United States Patent 8,648,037 (claim text provided in user prompt).
More… ↓
⤷ Start Trial
|
